Prediction of response and toxicities using plasma free DNA and plasma drug concentration in patients with NSCLC

• Project/Area Number: 19790566
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Respiratory organ internal medicine
• Research Institution: Osaka City University
• Principal Investigator: KIMURA Tatsuo Osaka City University, 大学院・医学研究科, 病院講師 (50382049)
• Project Period (FY): 2007 – 2008
• Project Status: Completed (Fiscal Year 2008)
• Budget Amount: ¥3,590,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥390,000); Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2007: ¥1,900,000 (Direct Cost: ¥1,900,000)
• Keywords: 肺癌 / 呼吸器病学 / アムルビシン / アムルビシノール / 薬物動態 / 薬力学 / 血漿濃度 / 非小細胞肺癌 / 血漿DNA

Research Abstract

AMR治療を施行された肺癌患者35例の血液中薬物濃度測定を行い臨床効果と比較検討を行った。AMR投与後4日目の薬剤血漿濃度を測定することにより、その血液毒性が予測出来ること、また、その血液毒性の強さは薬剤血漿濃度とSigmoid相関がみられ、シスプラチンとの併用においてはAMRの血液毒性はSigmoid Emax Modelにおいて左方偏移することがわかった。また、AMR-OHのCut Off値を13.0ng/mlとすると陽性反応的中度、陰性反応的中度は91%と63%であり、毒性の予測が簡便になった。

Research Products

• [Journal Article] Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities. (2009)
  • Author(s): Kimura T, et al.
  • Journal Title: Anticancer Drugs (掲載確定)
  • Peer Reviewed
• [Journal Article] Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities (2009)
  • Author(s): Kimura T, et.al.
  • Journal Title: Anti-Cancer Drugs (In press)
  • Peer Reviewed
• [Presentation] アムルビシン投与患者における臨床効果と薬物血中濃度との比較検討 (2008)
  • Author(s): 木村達郎
  • Organizer: 日本肺癌学会
  • Place of Presentation: 北九州
  • Year and Date: 2008-11-13
• [Presentation] アムルビシン投与患者における臨床効果と薬物血中濃度との比較検討 (2008)
  • Author(s): 木村達郎
  • Organizer: 日本癌治療学会
  • Place of Presentation: 名古屋
  • Year and Date: 2008-10-30
• [Presentation] Pharmacokinetic and pharmacodynamics (PK/PD) approach for myelosupressions of amrubicin (AMR) in patients with lung cancer (2008)
  • Author(s): Kimura T, et al
  • Organizer: American Society of Clinical Oncology
  • Place of Presentation: Chicago, Illinois, USA
  • Year and Date: 2008-05-30
• [Presentation] Pharmacokinetic and pharmacodynamics (PK/PD) approach for myelosup ressions of amrubicin (AMR) in patients with lung cancer (2008)
  • Author(s): Kimura T, et.al.
  • Organizer: American Society of Clinical Oncology
  • Place of Presentation: Chicago
  • Year and Date: 2008-05-30